)
MBX Biosciences (MBX) investor relations material
MBX Biosciences Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.MBX 4291 obesity program
Q4 unblinding of the phase I/IIa C1 cohort is the key near-term milestone; planned readouts cover 12-week weight loss and its trajectory, longitudinal GI tolerability, and PK.
C1 includes 30 subjects: 20 on active treatment and 10 on placebo; the expected PK profile includes a 26-day T-half Cmax, supporting once-monthly dosing.
Competitive 12-week weight-loss benchmark is 6%-8%, based on phase III data for tirzepatide and semaglutide; May’s blinded B1 data showed 7% aggregate weight lowering in six active and two placebo subjects.
May’s blinded B1 safety dataset showed one mild diarrhea case; the prodrug design targets a gradual 5-6-day rise to Cmax to potentially improve GI tolerability.
Phase IIb is planned for next year, assuming success, with multiple doses and schedules informed by the unblinded study; management expects the study’s totality of evidence to support moving into phase II.
Obesity portfolio and strategy
C2 started after C1 and is expected to inform phase II design; additional data flow and development plans were expected to be discussed later in Q4.
Management is working toward a commercially competitive single-injection device for a future phase III; vial and syringe are planned for phase IIb to avoid delaying its start.
Strategy is to demonstrate differentiation through phase I/IIa and phase IIb data, then seek a partner to support concurrent, multiple phase III studies.
MBX 6180 triple G preclinical data in non-human primates supported projection of a monthly dose; two other obesity assets are in IND-enabling studies, with potential future candidate nominations.
The platform is designed to engineer peptide release profiles from one hour to 1,000 hours; management cited a wide-open landscape for true once-monthly agents.
Canvuparatide and commercial plans
Twelve-month open-label extension data showed sustained clinical benefit for chronic hypoparathyroidism; phase III oPTimize recruitment remains on track for completion in H2 next year.
Patient and investigator engagement has been strong, with no observed impact from YORVIPATH on recruitment or timelines; the weekly administration drew interest.
Management plans to build a U.S. commercial organization and has begun pre-commercial work; it views the chronic hypoparathyroidism market as suitable for standalone commercialization.
YORVIPATH’s reported Q3 revenue run rate was ~$1.2 billion, with estimated market penetration of 5%-7%; management cited this as validation of unmet need and market potential.
- Canvuparatide advances in phase III as monthly obesity assets progress toward key data.MBX
3rd Annual Guggenheim Healthcare Innovation Conference - Canvuparatide Phase 3 began; $481.6M in liquidity supported runway into 2029.MBX
Q3 2026 - Advancing once-weekly and once-monthly peptide therapies with strong clinical and market momentum.MBX
Stifel 2026 Virtual Cardiometabolic Forum - Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027.MBX
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 net loss rose to $37.1M as R&D spending increased; cash reserves support operations into 2029.MBX
Q2 2026 - Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum.MBX
Corporate presentation - Phase III for once-weekly canvuparatide starts Q3 2024, with major 2026 data and strong financials.MBX
Piper Sandler 37th Annual Healthcare Conference - Once-weekly canvuparatide showed durable efficacy and safety at one year, supporting Phase III advancement.MBX
Study result - All director and auditor proposals were approved by stockholders at the annual meeting.MBX
AGM 2026
)
)
)
)
)
)
)
)